IKT Stock Analysis: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$2.44
0.23 (10.41%)
▲
5d:
+5.63%
30d:
+23.23%
90d:
+25.77%
HOLD
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: IKT is 7.5% above its trading range ($2.27). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: IKT is 7.5% above its trading range ($2.27). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $2.44, which is considered extended relative to its 30-day fair value range of $1.98 to $2.27.
Technical Outlook: Technically, IKT is in a uptrend. Immediate support is located at $2.12, while resistance sits at $2.53. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+171.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IKT is in a uptrend. Immediate support is located at $2.12, while resistance sits at $2.53. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+171.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.98 -
$2.27
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.1%
All Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.4%)
- BULLISH: Trading 171.5% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$1.98 -
$2.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.12
Resistance Level
$2.53
Current Trend
Uptrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.82
Wall Street Target
$6.00
(+171.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 04, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 55 HOLD |
